Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10825488rdf:typepubmed:Citationlld:pubmed
pubmed-article:10825488lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C0010132lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C0061355lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C0537521lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C0085862lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C1299583lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C1824528lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C0204695lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C1608386lld:lifeskim
pubmed-article:10825488lifeskim:mentionsumls-concept:C1549571lld:lifeskim
pubmed-article:10825488pubmed:issue1-2lld:pubmed
pubmed-article:10825488pubmed:dateCreated2000-8-7lld:pubmed
pubmed-article:10825488pubmed:abstractTextThe melanocortin-4 receptor (MC4-R) appears to be an important downstream mediator of the action of leptin. We examined to what extent the anorectic effects of cocaine- and amphetamine-regulated transcript (CART), glucagon-like peptide-1 (GLP-1) and corticotrophin releasing factor (CRF) might be mediated via MC4-R. alpha-Melanocyte stimulating hormone (alpha-MSH), the MC4-R agonist, administered intracerebroventricularly (ICV) at a dose of 1 nmol reduced food intake by approximately half. Agouti-related protein (Agrp) (83-132), a biologically active fragment of the endogenous MC4-R antagonist, administered ICV at a dose of 1 nmol completely blocked the anorectic effect of 1 nmol alpha-MSH. CART (55-102) (0.2 nmol), GLP-1 (3 nmol) and CRF (0.3 nmol) produced a reduction in feeding of approximately the same magnitude as 1 nmol alpha-MSH. Agrp (83-132) (1 nmol) administered ICV did not block the anorectic effects of CART (55-102) (1 h food intake, 0.2 nmol CART (55-102), 2.7+/-0.8 g vs. CART (55-102)+Agrp (83-132), 2.6+/-0.6 g, P=0.87; saline control 5.4+/-0.3 g, P<0.001 vs. both groups). Agrp (83-132) also did not block the anorectic effects of GLP-1 or CRF (1 h food intake, 0.3 nmol CRF, 0.7+/-0.3 g vs. CRF+Agrp (83-132), 0.7+/-0.3 g, P=0.91; 3 nmol GLP-1, 1.9+/-0.4 g vs. GLP-1+Agrp (83-132), 1.1+/-0. 5 g, P=0.23; saline control 5.0+/-0.6 g, P<0.001 vs. all four groups). Thus, as previous data suggests, GLP-1 and CRF do not appear to reduce food intake predominantly via MC4-R, we here demonstrate for the first time that CART, in addition to GLP-1 and CRF primarily acts via Agrp independent pathways.lld:pubmed
pubmed-article:10825488pubmed:languageenglld:pubmed
pubmed-article:10825488pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:citationSubsetIMlld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10825488pubmed:statusMEDLINElld:pubmed
pubmed-article:10825488pubmed:monthJunlld:pubmed
pubmed-article:10825488pubmed:issn0006-8993lld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:BloomS RSRlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:RossiMMlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:KimMMlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:EdwardsC MCMlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:AbbottC RCRlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:TaheriSSlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:MurphyK GKGlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:SunterDDlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:AbusnanaSSlld:pubmed
pubmed-article:10825488pubmed:authorpubmed-author:DakinC LCLlld:pubmed
pubmed-article:10825488pubmed:issnTypePrintlld:pubmed
pubmed-article:10825488pubmed:day2lld:pubmed
pubmed-article:10825488pubmed:volume866lld:pubmed
pubmed-article:10825488pubmed:ownerNLMlld:pubmed
pubmed-article:10825488pubmed:authorsCompleteYlld:pubmed
pubmed-article:10825488pubmed:pagination128-34lld:pubmed
pubmed-article:10825488pubmed:dateRevised2011-8-3lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:meshHeadingpubmed-meshheading:10825488...lld:pubmed
pubmed-article:10825488pubmed:year2000lld:pubmed
pubmed-article:10825488pubmed:articleTitleCocaine- and amphetamine-regulated transcript, glucagon-like peptide-1 and corticotrophin releasing factor inhibit feeding via agouti-related protein independent pathways in the rat.lld:pubmed
pubmed-article:10825488pubmed:affiliationICSM Endocrine Unit, Hammersmith Hospital, W12 0NN, London, UK.lld:pubmed
pubmed-article:10825488pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10825488pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10825488lld:pubmed